Skip to Content

LBA: Probably the Best in Class for Treatment of Plaque Psoriasis

At this year’s EADV Congress, Dr. Blauvelt, Oregon, USA, presented a Late Breaking Abstract with promising results for a potent and highly selective allosteric TYK2 inhibitor for the treatment of plaque psoriasis. The results show a clinically effective and generally safe oral therapy for treating patients with moderate-to-severe plaque psoriasis.

Andrew Blauvelt

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top